Kymera Therapeutics, Inc.

NASDAQ:KYMR

Biotechnology

Healthcare
$121.13 +1.67%

+$1.50 today

Market cap
$10.34B
Beta
2.03
P/E (TTM)
-28.3
EPS (TTM)
-$3.23
52W Low $36.65High $103.00

Volume 0.68M

Average 0.58M

KYMR Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

Kymera Therapeutics, Inc.NASDAQ: KYMR

Accounts Payables · Q2 FY2026 · quarter ended Jun 2026

Accounts payables dips below year-ago levels

Q2 FY2026 accounts payables of $3.94M (cash outflow) fell 4.6% year over year, behind the +1670.4% change in trailing-twelve-month accounts payables.

Context

  • Accounts payables amounted to 5.0% of revenue in FY2025, up 4.4 pp from a year earlier.
  • Accounts payables increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -4.6% toward the trailing-twelve-month pace of +1670.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$3.94M-144.7% QoQ
Last fiscal yearDec 2025
-$1.97M+543.0% YoY
LTMJun 2026
$3.39M+1670.4% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-4.6%——
1 year+543.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
(1.97M) USD
Year-over-year change
-543.0%

Accounts Payables vs competitors

How KYMR compares with its peers on the latest reported figures

  • KYMR's LTM Jun 2026 accounts payables of $3.39M is the 3rd largest of the 5 companies compared; the peer median is $817.5K.
  • Its year-over-year change of +1670.4% is the highest of 5, against a peer median of +177.1%.
  • Accounts payables amounts to 3.2% of revenue for KYMR, versus a peer median of 3.6%.
KYMR Competitors Peer median
Accounts Payables for KYMR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NRIXNurix Therapeutics, Inc.LTM Aug 2026$25.05M +537.3%—3.6%
ARVNArvinas, Inc.LTM Mar 2026$7.7M -527.8%—8.6%
KYMRKymera Therapeutics, Inc.LTM Jun 2026$3.39M +1670.4%—3.2%
GLUEMonte Rosa Therapeutics, Inc.LTM Mar 2026$1.54M +244.4%+164.1%3.6%
CCCCC4 Therapeutics, Inc.LTM Mar 2026$92K +109.7%-48.0%0.3%
Peer median (excluding KYMR) $817.5K+177.1%+58.0%3.6%

Competitors are the stored peer set for KYMR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(100.22M)(154.81M)(146.96M)(223.86M)(311.35M)
Depreciation & Amortization2.4M2.98M3.57M7.37M8.31M
Deferred Income Tax00000
Stock-Based Compensation24.97M35.48M43.12M55.01M59.9M
Change in Working Capital(61.92M)(37.62M)9.25M(23.97M)15.27M
Accounts Receivables577K(2.4M)(16.23M)17.82M947K
Inventory8.71M2.4M000
Accounts Payables54K253K0(307K)(1.97M)
Other Working Capital(71.26M)(37.88M)25.48M(41.48M)16.29M
Other Non-Cash Items5.83M889K(11.8M)(9.06M)(5.02M)
Operating Cash Flow(128.95M)(153.09M)(102.83M)(194.5M)(232.89M)
Capital Expenditures(1.6M)(2.84M)(34.48M)(12.84M)(1.45M)
Acquisitions (Net)5.81M(20.52M)000
Purchases of Investments(456.4M)(445.97M)0(901.23M)(1.01B)
Sales of Investments358.17M469.33M0496M479.14M
Other Investing Activities(5.81M)20.52M174.37M13.98M8.88M
Investing Cash Flow(99.84M)20.52M139.89M(404.08M)(521.06M)
Debt Repayment(849K)(1.13M)(76K)(1.58M)(1.49M)
Common Stock Issued243.11M149.83M0596.62M992.21M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities8.02M4.3M4.27M13.81M0
Financing Cash Flow250.28M153M4.19M608.85M990.71M
Effect of Forex Changes00000
Net Change in Cash21.5M20.43M41.25M10.27M236.76M
Free Cash Flow(130.54M)(155.92M)(137.31M)(207.34M)(234.34M)

Kymera Therapeutics, Inc.

NASDAQ:KYMR

Intrinsic Alpha fair value

Locked

Current Price

$121.13

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.